Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL CHRISTOPHER JOYCE

Allopathic & Osteopathic Physicians Dermatology Pediatric Dermatology

NPI
1700045713
CMS profile
77679
Location
SKOKIE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$92,566.63

73 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $62,882.90 44
ABBVIE INC. $16,528.88 15
SANOFI US SERVICES INC. $10,187.00 6
Incyte Corporation $2,845.09 4
Regeneron Healthcare Solutions, Inc. $67.81 2
Arcutis Biotherapeutics, Inc. $34.22 1
PFIZER INC. $20.73 1

Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL CHRISTOPHER JOYCE

NPI 1700045713 · CMS profile ID 77679

Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology

SKOKIE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700045713?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700045713?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700045713?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOEL CHRISTOPHER JOYCE, NPI 1700045713, CMS profile ID 77679, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 73 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1700045713?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

73 matching records · $92,566.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 73 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 73.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $30.2912/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202141849 CMS
ABBVIE INC. $19.1811/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202141847 CMS
ABBVIE INC. $3,750.0011/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202141845 CMS
GENZYME CORPORATION $250.0010/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200561 CMS
ABBVIE INC. $111.3510/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202141843 CMS
GENZYME CORPORATION $8,967.0010/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200523 CMS
GENZYME CORPORATION $424.9110/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200525 CMS
GENZYME CORPORATION $324.5410/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200527 CMS
GENZYME CORPORATION $100.5010/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200545 CMS
GENZYME CORPORATION $4,697.0010/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200547 CMS
GENZYME CORPORATION $268.5110/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200549 CMS
GENZYME CORPORATION $162.5210/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200551 CMS
GENZYME CORPORATION $1,250.0009/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200517 CMS
GENZYME CORPORATION $250.0009/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200565 CMS
GENZYME CORPORATION $48.6108/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200507 CMS
ABBVIE INC. $234.8108/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202141841 CMS
ABBVIE INC. $3,750.0008/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202141839 CMS
Incyte Corporation $2,400.0008/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226139671 CMS
Incyte Corporation $250.0508/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226139677 CMS
SANOFI US SERVICES INC. $1,336.0007/30/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1233200539 CMS
ABBVIE INC. $44.1807/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202141837 CMS
Arcutis Biotherapeutics, Inc. $34.2207/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252349811 CMS
GENZYME CORPORATION $50.3707/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200497 CMS
ABBVIE INC. $113.5307/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202141835 CMS
Incyte Corporation $180.4607/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226021717 CMS
GENZYME CORPORATION $812.0007/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200501 CMS
ABBVIE INC. $254.6807/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202141833 CMS
PFIZER INC. $20.7306/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228917815 CMS
GENZYME CORPORATION $250.0006/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200503 CMS
ABBVIE INC. $3,750.0006/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202141831 CMS
Regeneron Healthcare Solutions, Inc. $35.4806/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212953738 CMS
GENZYME CORPORATION $250.0005/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200559 CMS
ABBVIE INC. $15.1705/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202141829 CMS
GENZYME CORPORATION $5.6205/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200489 CMS
GENZYME CORPORATION $6,496.0005/02/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200509 CMS
GENZYME CORPORATION $249.6605/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200511 CMS
GENZYME CORPORATION $308.9605/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200513 CMS
GENZYME CORPORATION $86.0005/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200567 CMS
GENZYME CORPORATION $22.4005/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200569 CMS
GENZYME CORPORATION $37.8005/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200571 CMS
GENZYME CORPORATION $39.3004/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200485 CMS
GENZYME CORPORATION $3,843.0004/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200487 CMS
GENZYME CORPORATION $8,967.0004/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200473 CMS
GENZYME CORPORATION $530.8204/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200475 CMS
GENZYME CORPORATION $2,960.8004/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200477 CMS
GENZYME CORPORATION $52.5904/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200479 CMS
GENZYME CORPORATION $5,551.0004/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233200481 CMS
GENZYME CORPORATION $530.8004/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233200483 CMS
GENZYME CORPORATION $6.9304/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200467 CMS
GENZYME CORPORATION $5.4604/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233200459 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $700.40 2
PY2020 $2,376.00 1
PY2021 $2,246.65 3
PY2022 $2,632.70 9
PY2023 $23,671.61 40
PY2024 $79,055.13 79
PY2025 $92,566.63 73

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,750.00 4
PY2025 Principal investigator $694,810.55 184
PY2024 Recipient $7,148.03 20
PY2024 Principal investigator $657,792.45 167
PY2023 Recipient $3,281.97 14
PY2023 Principal investigator $421,779.06 92
PY2022 Recipient $1,517.38 3
PY2022 Principal investigator $234,287.76 66
PY2021 Principal investigator $111,180.61 56
PY2020 Principal investigator $343,493.78 70
PY2019 Principal investigator $4,975.53 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

69 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $5,541.43 12/29/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905247373
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/27/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627641
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/27/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627653
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/27/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627667
Principal investigator 1 SANOFI US SERVICES INC. $394.10 12/27/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627677
Principal investigator 1 Janssen Research & Development, LLC $2,293.32 12/26/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885252309
Principal investigator 1 Janssen Research & Development, LLC $2,293.32 12/26/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885252311
Principal investigator 1 Janssen Research & Development, LLC $4,586.64 12/26/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885252313
Principal investigator 1 Janssen Research & Development, LLC $4,586.64 12/26/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885252315
Principal investigator 1 Janssen Research & Development, LLC $15,320.56 12/21/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 885224085
Principal investigator 1 Janssen Research & Development, LLC $15,750.00 12/19/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
CNTO1959PSO3018 No dispute reported 06/30/2026 885224083
Principal investigator 1 Incyte Corporation $1,046.40 12/09/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905247371
Principal investigator 1 ABBVIE INC. $2,114.53 12/08/2022 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 889768011
Principal investigator 1 Incyte Corporation $12,300.00 12/08/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis No dispute reported 06/30/2026 905217585
Principal investigator 1 Incyte Corporation $1,795.73 12/01/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905247369
Principal investigator 1 Janssen Research & Development, LLC $20,153.41 11/28/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885252305
Principal investigator 1 Janssen Research & Development, LLC $20,153.41 11/28/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885252307
Principal investigator 1 Incyte Corporation $2,334.95 11/03/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905247367
Principal investigator 1 Janssen Research & Development, LLC $7,554.49 10/27/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885252297
Principal investigator 1 Janssen Research & Development, LLC $7,554.49 10/27/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885252299
Principal investigator 1 Janssen Research & Development, LLC $5,348.17 10/27/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885252301
Principal investigator 1 Janssen Research & Development, LLC $5,348.17 10/27/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 885252303
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 10/11/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Open-label 12-week Longitudinal Exploratory Study to Assess Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of PEDISTAD Patients No dispute reported 06/30/2026 935627621
Principal investigator 1 SANOFI US SERVICES INC. $225.72 10/11/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Open-label 12-week Longitudinal Exploratory Study to Assess Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of PEDISTAD Patients No dispute reported 06/30/2026 935627633
Principal investigator 1 ABBVIE INC. $2,114.53 10/06/2022 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 889767993
Principal investigator 1 Incyte Corporation $1,343.03 10/05/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905247355
Recipient Regeneron Pharmaceuticals, Inc. $734.55 10/01/2022 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 938603437
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/26/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627489
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/26/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627499
Principal investigator 1 SANOFI US SERVICES INC. $394.10 09/26/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627511
Principal investigator 1 ABBVIE INC. $2,462.93 09/08/2022 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 889767987
Principal investigator 1 Incyte Corporation $2,521.79 08/26/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905247341
Principal investigator 1 ABBVIE INC. $2,149.87 08/16/2022 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 889767983
Principal investigator 1 Incyte Corporation $5,061.61 08/02/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905247339
Principal investigator 1 SANOFI US SERVICES INC. $10,000.00 07/20/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Open-label 12-week Longitudinal Exploratory Study to Assess Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of PEDISTAD Patients No dispute reported 06/30/2026 935627468
Principal investigator 1 SANOFI US SERVICES INC. $850.00 07/20/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Open-label 12-week Longitudinal Exploratory Study to Assess Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of PEDISTAD Patients No dispute reported 06/30/2026 935627477
Recipient SANOFI US SERVICES INC. $500.00 07/07/2022 Covered Recipient Physician Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935570125
Principal investigator 1 SANOFI US SERVICES INC. $394.10 07/05/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627389
Principal investigator 1 SANOFI US SERVICES INC. $394.10 07/05/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627401
Principal investigator 1 SANOFI US SERVICES INC. $394.10 07/05/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627411
Principal investigator 1 SANOFI US SERVICES INC. $394.10 07/05/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627423
Principal investigator 1 SANOFI US SERVICES INC. $394.10 07/05/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627433
Principal investigator 1 SANOFI US SERVICES INC. $394.10 07/05/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627445
Principal investigator 1 SANOFI US SERVICES INC. $394.10 07/05/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627457
Recipient Regeneron Pharmaceuticals, Inc. $282.83 07/01/2022 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 938603435
Principal investigator 1 Incyte Corporation $1,890.24 06/24/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905247329
Principal investigator 1 ABBVIE INC. $3,803.30 06/16/2022 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 889767967
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,095.00 06/06/2022 Non-covered Recipient Entity
Northshore University Health System-Dermatology Clinical Trials Unit
Phase II Umbrella AD - A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 933191663
Principal investigator 1 Incyte Corporation $1,890.24 05/31/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905247313
Principal investigator 1 SANOFI US SERVICES INC. $288.42 05/25/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topical Prescription Therapies or When Those Therapies Are Not Medically Advisable No dispute reported 06/30/2026 935627367
Principal investigator 1 SANOFI US SERVICES INC. $288.42 05/25/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients Whose Disease is Not Adequately Controlled With Topical Prescription Therapies or When Those Therapies Are Not Medically Advisable No dispute reported 06/30/2026 935627377
Principal investigator 1 Incyte Corporation $1,795.73 05/03/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905247311
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,700.00 04/21/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Phase II Umbrella Study - A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 933191727
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/23/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627251
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/23/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627263
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/23/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627275
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/23/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627287
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/23/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627297
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/23/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627309
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/23/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627321
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/23/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627333
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/23/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627345
Principal investigator 1 SANOFI US SERVICES INC. $394.10 03/23/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) No dispute reported 06/30/2026 935627355
Principal investigator 1 ABBVIE INC. $2,238.03 03/17/2022 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 889767951
Principal investigator 1 Eli Lilly and Company $8,415.00 03/17/2022 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917819237
Principal investigator 1 Eli Lilly and Company $15,491.00 02/24/2022 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917819231
Principal investigator 1 ABBVIE INC. $1,595.17 02/16/2022 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up) No dispute reported 06/30/2026 889767939
Principal investigator 1 ABBVIE INC. $1,653.67 01/12/2022 Covered Recipient Teaching Hospital
NORTHSHORE UNIVERSITY HEALTHSYSTEM
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (AD Up) No dispute reported 06/30/2026 889767933
Principal investigator 1 Incyte Corporation $10,880.00 01/07/2022 Covered Recipient Teaching Hospital
Northshore University Healthsystem
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 905247297